Monoclonal Antibody Therapeutics Market

SKU: DMBT12 | Last Updated On: Sep 25 2021 | No. of Pages: 180 | Available Formats

> Global Monoclonal Antibody Therapeutics Market Expected to reach a high CAGR of 7.40% By 2028: DataM Intelligence

Global Monoclonal Antibody Therapeutics Market is segmented By Product Type (Naked, Fusion Protein, Antibody fragment, Conjugate, Multi-specific), By Application (Cancer, Autoimmune Diseases, Infectious Diseases, Others), By Production Source (Human, Humanized, Chimeric, Others), By End User, Hospitals, Private Clinics, Research Institutes), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

Market Overview

The Global Monoclonal Antibody Therapeutics Market is expected to grow at a CAGR during the forecasting period (2021-2028).

Monoclonal Antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAb) to bind mono specifically to specific cells or proteins. Therapeutic monoclonal antibodies harness the highly evolved specificity of adaptive immunity to fight disease. Monoclonal antibodies are being used to treat severe and chronic conditions.

 

Source: DataM Intelligence Analysis (2020)

Market Dynamics

The rising incidence of cancer is expected to increase demand for infusion therapies, thereby contributing to significant growth of the monoclonal antibodies market.

Rising incidence of cancer and other chronic diseases drive the market growth

The global market for the Monoclonal Antibody Therapeutics Market is primarily driven by the rising incidence of cancer and other chronic diseases coupled with the rise in R&D activities in genomics. According to the World Health Organization, The global cancer burden has risen to 18.1 million new cases and 9.6 million deaths in 2018. Additionally, the increasing drug approvals and launches of novel monoclonal antibodies for various diseases treatments such as cancer, robust research, and development of monoclonal antibodies for multiple diseases and technologies such as the advent of mammalian cell culture, process, and formulation technology is expected to be significant market opportunities. As of 2017, 47 monoclonal antibody products have been approved in the US and Europe to treat a variety of diseases. Continuing at the current approval rate of nearly four new products per year, around 70 monoclonal antibody products will be on the market by 2020, with combined global sales of almost USD 125 billion..

Increasing regulatory approvals and launch of therapies is driving the market growth  

Rise in approval of monoclonal antibodies by regulatory offices favors the launch of innovative therapeutics, which is expected to drive the market's growth over the forecast period. For instance, in 2018, Chugai Pharmaceutical Co., Ltd. (part of Roche Holding AG) announced that it received Breakthrough Therapy Designation from the U.S. FDA for its product, Satralizumab. In May 2018, Johnson & Johnson received the U.S. Food and Drug Administration's approval for its monoclonal antibody, Darzalex (daratumumab), in combination with Velcade (bortezomib), melphalan, and prednisone, for the treatment of patients with newly diagnosed multiple myeloma, not eligible for autologous stem cell transplant (ASCT).

Higher costs and strict regulatory measures is likely to hamper market growth

However, higher costs and strict regulatory measures resulting in lengthy approval procedures may restrict the market growth. Drugs formed from mAbs is that they are very distinct and have restricted targets. This is because they associate with cells and do not penetrate them. This, to some degree, has hampered the global monoclonal antibodies market. Another problem in using mAbs is that they require to be injected, unlike small molecule drugs.

 Market Industry Analysis

Opportunities:

 

Supply Chain Analysis:

 

 COVID-19 Impact Analysis

The COVID 19 pandemic and lockdown in various countries across the globe have affected the financial status of businesses in all sectors. In addition, the lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Therefore, the guidelines issued by the U.S. Food and Drug Administration (FDA) include general considerations to assist sponsors and researchers, which ensure the safety of trial participants, compliance with good clinical practice (GCP), and minimize risks to trial integrity for the duration of the COVID-19 public health emergency. In addition, the appendix of the guidelines also provides answers to some general questions, which the U.S. Food and Drug Administration (FDA) had received from various sponsors and researchers about conducting clinical trials during the COVID-19 public health emergency.

Segment Analysis

Cancer segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)   

Cancer has the dominating market share owing to the surge in cancer incidents and the extensive use of monoclonal antibody therapeutics in cancer treatment. According to the World Health Organization, one in 5 men and one in 6 women worldwide develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease.

Worldwide, the total number of alive within five years of a cancer diagnosis, called the 5-year prevalence, is estimated to be 43.8 million. Moreover, due to minimizing adverse effects associated with monoclonal antibody therapeutics use, they have proven to be an excellent alternative treatment for cancer compared to drugs and chemotherapy. Additionally, the growing drug pipeline coupled with treatment approvals and clinical trials is anticipated to provide future growth opportunities for the market.

For instance, Keytruda (Pembrolizumab), a monoclonal antibody used for the treatment of different types of cancer, costs about US$ 2,250 for a vial of 50 mg. In addition, the loss of patents is also expected to hinder the market growth over the forecast period. For instance, the Rituximab (Rituxan) product of Genentech, Inc. (Roche) failed its patent in the U.S. and Europe.

Source: DataM Intelligence Analysis (2020)

Geographical Analysis

North America region holds the largest market share in the global monoclonal antibody therapeutics market

North America is the dominant share in the global monoclonal antibody therapeutics market and can be attributed to the presence of well-established healthcare infrastructure. Moreover, its broad base of the patient population, well-established reimbursement policies, high awareness regarding diseases, government support in infection control & management, rising incidence of lifestyle-associated diseases, and higher investment in R&D activities by the government for cancer contribute to the growth of North America's share. Domestically, the US drug industry spends approximately $45 billion annually on R&D. According to the Centers for Disease Control and Prevention (CDC), 6 in 10 adults in the US have a chronic disease, of which 4 in 10 Adults have two or more.

The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services in the USA regulating the monoclonal antibodies and pharmaceutical drugs market. Increasing product launches and regulatory support for the treatment of rare diseases by USFDA is expected to support the region's monoclonal antibody therapeutics market growth.

For instance, the U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.), a human monoclonal antibody, for the treatment of a rare disease metastatic Merkel cell carcinoma (MCC). Similarly, the U.S FDA granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab), a humanized, engineered monoclonal antibody, to treat people with locally advanced or metastatic urothelial carcinoma.

Source: DataM Intelligence Analysis (2020)

Competitive Landscape

The monoclonal antibody therapeutics market is moderately competitive with presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., CASI Pharmaceuticals, Eli Lilly and Co., Merck & Co., Inc., Changchun Zhongyingfeng Science And Technology Co., Ltd, Hangzhou Immuno Biotech Co. Ltd, Nantong Egens Biotechnology Co. Ltd among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the monoclonal antibody therapeutics market globally.    

Monoclonal Antibody Therapeutics Market Key Companies to Watch

CASI Pharmaceuticals

Overview: CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China, Taiwan, Hong Kong, and Macau.

Product Portfolio: The Company develops and commercializes the oncology drugs and drug candidates. CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin’s Lymphoma Patients.

Key Development: In April 2019, CASI Pharmaceuticals, announced the signing of a license agreement for exclusive worldwide rights to the investigational anti-CD38 monoclonal antibody (Mab) TSK011010 program from Black Belt Therapeutics Limited. Under the contract, CASI will be responsible for all development and commercialization activities of the TSK011010 program.

Why Purchase the Report?

  • Visualize the composition of the monoclonal antibody therapeutics market segmentation by product type, application, production source and end user highlighting the key commercial assets and players.
  • Identify commercial opportunities in monoclonal antibody therapeutics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of monoclonal antibody therapeutics market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global monoclonal antibody therapeutics market report would provide an access to an approx. 61 market data table, 55 figures and 200 pages.  

 

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Monoclonal Antibody Therapeutics Market - By Product Type

  • Naked
  • Fusion Protein
  • Antibody fragment
  •  Conjugate
  •  Multi-specific

Global Monoclonal Antibody Therapeutics Market - By Application

  • Cancer
  •  Autoimmune Diseases
  •  Infectious Diseases
  • Others

Global Monoclonal Antibody Therapeutics Market -By Production Source

  • Human
  • Humanized
  • Chimeric
  • Others

Global Monoclonal Antibody Therapeutics Market - By End User

  • Hospital
  • Private Clinics
  • Research Institutes

Global Monoclonal Antibody Therapeutics Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

  1. Global Monoclonal Antibody Therapeutics Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Global Monoclonal Antibody Therapeutics Market – Market Definition and Overview

  3. Global Monoclonal Antibody Therapeutics Market – Executive Summary

    1. Market Snippet by Product Type
    2. Market Snippet by Application
    3. Market Snippet by Production Source
    4. Market Snippet by End User
    5. Market Snippet by Region
  4. Global Monoclonal Antibody Therapeutics Market – Market Dynamics

    1. Market Impacting Factors
      1. Drivers
        1. Rising incidence of cancer and other chronic diseases drive the market growth
        2. Increasing regulatory approvals and launch of therapies is driving the market growth  
      2. Restraints:
        1. Higher costs and strict regulatory measures is likely to hamper market growth   
      3. Opportunity
      4. Impact Analysis
  5. Global Monoclonal Antibody Therapeutics Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Supply Chain Analysis
    3. Pricing Analysis
    4. Regulatory Analysis
    5. Reimbursement Analysis
    6. Unmet Needs
  6. Global Monoclonal Antibody Therapeutics Market – COVID-19 Analysis

    1. Analysis of Covid-19 on the Market
      1. Before COVID-19 Market Scenario
      2. Present COVID-19 Market Scenario
      3. After COVID-19 or Future Scenario
    2. Pricing Dynamics Amid Covid-19
    3. Demand-Supply Spectrum
    4. Government Initiatives Related to the Market During Pandemic
    5. Manufacturers Strategic Initiatives
    6. Conclusion 
  7. Global Monoclonal Antibody Therapeutics Market – By Product Type

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
      2. Market Attractiveness Index, By Product Type Segment
    2. Naked*
      1. Introduction
      2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. Fusion Protein
    4.  Antibody fragment
    5.  Conjugate
    6.  Multi-specific
  8. Global Monoclonal Antibody Therapeutics Market – By Application

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
      2. Market Attractiveness Index, By Application
    2. Cancer*
      1. Introduction
      2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. Autoimmune Diseases
    4.  Infectious Diseases
    5.  Others
  9. Global Monoclonal Antibody Therapeutics Market – By Production Source

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Production Source
      2. Market Attractiveness Index, By Production Source
    2. Human*
      1. Introduction
      2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. Humanized
    4.  Chimeric
    5.  Others
  10. Global Monoclonal Antibody Therapeutics Market – By End User

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
      2. Market Attractiveness Index, By End User Segment
    2. Hospitals *
      1. Introduction
      2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. Private Clinics
    4. Research Institutes
  11. Global Monoclonal Antibody Therapeutics Market – By Region

    1. Introduction
      1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Production Source
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Production Source
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Production Source
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Production Source
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Production Source
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  12. Global Monoclonal Antibody Therapeutics Market – Competitive Landscape

    1. Key Developments and Strategies
    2. Company Share Analysis
    3. Product Benchmarking
    4. List of key companies to watch
    5. List of the company with disruptive technology
    6. List of start-up companies
  13. Global Monoclonal Antibody Therapeutics Market- Company Profiles

    1. Pfizer Inc*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Novartis AG
    3.  Bayer AG
    4.  Sanofi S.A.
    5.  F. Hoffmann-La Roche AG
    6.  Eli Lilly and Co.
    7.  Merck & Co., Inc.
    8.  Changchun Zhongyingfeng Science And Technology Co. Ltd
    9. Hangzhou Immuno Biotech Co. Ltd
    10.  Nantong Egens Biotechnology Co. Ltd(*LIST NOT EXHAUSTIVE)
  14. Global Monoclonal Antibody Therapeutics Market – DataM   

    1.     Appendix
    2. About Us and Services
    3. Contact Us

List of Tables & Figures

List of Tables

Table 01   Global Monoclonal Antibody Therapeutics Market Value, By Product Type, 2020, 2024 & 2028 ($ Million)

Table 02   Global Monoclonal Antibody Therapeutics Market Value, By Application, 2020, 2024 & 2028 ($ Million)

Table 03   Global Monoclonal Antibody Therapeutics Market Value, By End User, 2020, 2024 & 2028 ($ Million)

Table 04   Global Monoclonal Antibody Therapeutics Market Value, By Region, 2020, 2024 & 2028 ($ Million)

Table 05   Global Monoclonal Antibody Therapeutics Market Value, By Product Type, 2020, 2024 & 2028 ($ Million)

Table 06   Global Monoclonal Antibody Therapeutics Market Value, By Product Type, 2018-2028 ($ Million)

Table 07   Global Monoclonal Antibody Therapeutics Market Value, By Application, 2020, 2024 & 2028 ($ Million)

Table 08  Global Monoclonal Antibody Therapeutics Market Value, By Application, 2018-2028 ($ Million)

Table 09   Global Monoclonal Antibody Therapeutics Market Value, By End User, 2020, 2024 & 2028 ($ Million)

Table 10   Global Monoclonal Antibody Therapeutics Market Value, By End User, 2018-2028 ($ Million)

Table 11    Global Monoclonal Antibody Therapeutics Market Value, By Region, 2020, 2024 & 2028 ($ Million)

Table 12   Global Monoclonal Antibody Therapeutics Market Value, By Region, 2018-2028 ($ Million)

Table 13   North America Monoclonal Antibody Therapeutics Market Value, By Product Type, 2018-2028 ($ Million)

Table 14   North America Monoclonal Antibody Therapeutics Market Value, By Application, 2018-2028 ($ Million)

Table 15   North America Monoclonal Antibody Therapeutics Market Value, By End User, 2018-2028 ($ Million)

Table 16   North America Monoclonal Antibody Therapeutics Market Value, By Country, 2018-2028 ($ Million)

Table 17    South America Monoclonal Antibody Therapeutics Market Value, By Product Type, 2018-2028 ($ Million)

Table 18   South America Monoclonal Antibody Therapeutics Market Value, By Application, 2018-2028 ($ Million)

Table 19   South America Monoclonal Antibody Therapeutics Market Value, By End User, 2018-2028 ($ Million)

Table 20   South America Monoclonal Antibody Therapeutics Market Value, By Country, 2018-2028 ($ Million)

Table 21   Europe Monoclonal Antibody Therapeutics Market Value, By Product Type, 2018-2028 ($ Million)

Table 22   Europe Monoclonal Antibody Therapeutics Market Value, By Application, 2018-2028 ($ Million)

Table 23   Europe Monoclonal Antibody Therapeutics Market Value, By End User, 2018-2028 ($ Million)

Table 24   Europe Monoclonal Antibody Therapeutics Market Value, By Country, 2018-2028 ($ Million)

Table 25   Asia-Pacific Monoclonal Antibody Therapeutics Market Value, By Product Type, 2018-2028 ($ Million)

Table 26   Asia-Pacific Monoclonal Antibody Therapeutics Market Value, By Application, 2018-2028 ($ Million)

Table 27   Asia-Pacific Monoclonal Antibody Therapeutics Market Value, By End User, 2018-2028 ($ Million)

Table 28   Asia-Pacific Monoclonal Antibody Therapeutics Market Value, By Country, 2018-2028 ($ Million)

Table 29   Middle East & Africa Monoclonal Antibody Therapeutics Market Value, By Product Type, 2018-2028 ($ Million)

Table 30   Middle East & Africa Monoclonal Antibody Therapeutics Market Value, By Application, 2018-2028 ($ Million)

Table 31   Middle East & Africa Monoclonal Antibody Therapeutics Market Value, By End User, 2018-2028 ($ Million)

Table 32   Pfizer Inc.: Overview

Table 33   Pfizer Inc.: Product Portfolio

Table 34   Pfizer Inc.: Key Developments

Table 35   Novartis AG: Overview

Table 36   Novartis AG: Product Portfolio

Table 37   Novartis AG: Key Developments

Table 38   Bayer AG: Overview

Table 39   Bayer AG: Product Portfolio

Table 40   Bayer AG: Key Developments

Table 41   Sanofi S.A.: Overview

Table 42   Sanofi S.A.: Product Portfolio

Table 43   Sanofi S.A.: Key Developments

Table 44   F. Hoffmann-La Roche AG: Overview

Table 45   F. Hoffmann-La Roche AG: Product Portfolio

Table 46   F. Hoffmann-La Roche AG: Key Developments

Table 47   Eli Lilly and Co: Overview

Table 48   Eli Lilly and Co: Product Portfolio

Table 49   Eli Lilly and Co: Key Developments

Table 50   Merck & Co., Inc.: Overview

Table 51   Merck & Co., Inc.: Product Portfolio

Table 52   Merck & Co., Inc.: Key Developments

Table 53   CHANGCHUN ZHONGYINGFENG SCIENCE AND TECHNOLOGY CO., LTD: Overview

Table 54   CHANGCHUN ZHONGYINGFENG SCIENCE AND TECHNOLOGY CO., LTD: Product Portfolio

Table 55   CHANGCHUN ZHONGYINGFENG SCIENCE AND TECHNOLOGY CO., LTD: Key Developments

Table 56   Hangzhou Immuno Biotech Co. Ltd: Overview

Table 57   Hangzhou Immuno Biotech Co. Ltd: Product Portfolio

Table 58   Hangzhou Immuno Biotech Co. Ltd: Key Developments

Table 59   "Nantong Egens Biotechnology Co. Ltd: Overview"

Table 60   "Nantong Egens Biotechnology Co. Ltd: Product Portfolio"

Table 61   "Nantong Egens Biotechnology Co. Ltd: Key Developments"

List of Figures

Figure 01 Global Monoclonal Antibody Therapeutics Market Share, By Product Type, 2020 & 2028 (%)

Figure 02 Global Monoclonal Antibody Therapeutics Market Share, By Application, 2020 & 2028 (%)

Figure 03 Global Monoclonal Antibody Therapeutics Market Share, By End User, 2020 & 2028 (%)

Figure 04 Global Monoclonal Antibody Therapeutics Market Share, By Region, 2020 & 2028 (%)

Figure 05 Global Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 06 Global Monoclonal Antibody Therapeutics Market Y-o-Y Growth, By Product Type, 2020-2028(%)

Figure 07 Naked: Global Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 08  Fusion Protein: Global Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 09 Antibody fragment: Global Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 10 Conjugate: Global Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 11  Multi-specific: Global Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 12 Global Monoclonal Antibody Therapeutics Market Y-o-Y Growth, By Application, 2020-2028(%)

Figure 13 Cancer: Global Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 14 Autoimmune Diseases: Global Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 15 Infectious Diseases: Global Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 16 Others: Global Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 17  Global Monoclonal Antibody Therapeutics Market Y-o-Y Growth, By End User, 2020-2028(%)

Figure 18 Hospitals: Global Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 19 Private Clinics: Global Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 20 Research Institutes: Global Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 21 Global Monoclonal Antibody Therapeutics Market Y-o-Y Growth, By Region, 2020-2028(%)

Figure 22 North America Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 23 North America Monoclonal Antibody Therapeutics Market Share, By Product Type, 2020 & 2028 (%)

Figure 24 North America Monoclonal Antibody Therapeutics Market Share, By Application, 2020 & 2028 (%)

Figure 25 North America Monoclonal Antibody Therapeutics Market Share, By End User, 2020 & 2028 (%)

Figure 26 North America Monoclonal Antibody Therapeutics Market Share, By Country, 2020 & 2028 (%)

Figure 27 South America Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 28 South America Monoclonal Antibody Therapeutics Market Share, By Product Type, 2020 & 2028 (%)

Figure 29 South America Monoclonal Antibody Therapeutics Market Share, By Application, 2020 & 2028 (%)

Figure 30 South America Monoclonal Antibody Therapeutics Market Share, By End User, 2020 & 2028 (%)

Figure 31 South America Monoclonal Antibody Therapeutics Market Share, By Country, 2020 & 2028 (%)

Figure 32 Europe Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 33 Europe Monoclonal Antibody Therapeutics Market Share, By Product Type, 2020 & 2028 (%)

Figure 34 Europe Monoclonal Antibody Therapeutics Market Share, By Application, 2020 & 2028 (%)

Figure 35 Europe Monoclonal Antibody Therapeutics Market Share, By End User, 2020 & 2028 (%)

Figure 36 Europe Monoclonal Antibody Therapeutics Market Share, By Country, 2020 & 2028 (%)

Figure 37 Asia-Pacific Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 38 Asia-Pacific Monoclonal Antibody Therapeutics Market Share, By Product Type, 2020 & 2028 (%)

Figure 39 Asia-Pacific Monoclonal Antibody Therapeutics Market Share, By Application, 2020 & 2028 (%)

Figure 40 Asia-Pacific Monoclonal Antibody Therapeutics Market Share, By End User, 2020 & 2028 (%)

Figure 41 Asia-Pacific Monoclonal Antibody Therapeutics Market Share, By Country, 2020 & 2028 (%)

Figure 42 Middle East & Africa Monoclonal Antibody Therapeutics Market Value, 2018-2028 ($ Million)

Figure 43 Middle East & Africa Monoclonal Antibody Therapeutics Market Share, By Product Type, 2020 & 2028 (%)

Figure 44 Middle East & Africa Monoclonal Antibody Therapeutics Market Share, By Application, 2020 & 2028 (%)

Figure 45 Middle East & Africa Monoclonal Antibody Therapeutics Market Share, By End User, 2020 & 2028 (%)

Figure 46 Pfizer Inc.: Financials

Figure 47 Novartis AG: Financials

Figure 48 Bayer AG: Financials

Figure 49 Sanofi S.A.: Financials

Figure 50 F. Hoffmann-La Roche AG: Financials

Figure 51 Eli Lilly and Co: Financials

Figure 52 Merck & Co., Inc.: Financials

Figure 53 CHANGCHUN ZHONGYINGFENG SCIENCE AND TECHNOLOGY CO., LTD: Financials

Figure 54 Hangzhou Immuno Biotech Co. Ltd: Financials

Figure 55 "Nantong Egens Biotechnology Co. Ltd: Financials"

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Year-End Offer from
DataM Intelligence

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest